Rapamycin + Metformin

Verdict: Probable (in mice — driven primarily by rapamycin) / Suggestive (in humans) Last reviewed: 2026-04-25

TL;DR

The Strong et al. 2016 ITP cohort tested rapamycin + metformin and showed lifespan extension consistent with rapamycin alone — i.e., metformin did not appear to add benefit beyond what rapamycin produced. This is methodologically informative: it suggests the combination's benefit comes primarily from rapamycin, with metformin not contributing meaningfully. The popular "metformin + rapamycin stack" framing in longevity medicine is at best supported by the rapamycin component.

Component verdicts

• Rapamycin alone: Probable (anchor) → see interventions/rapamycin.md
• Metformin alone: Mixed (longevity case in non-diabetics is weak; ITP showed no lifespan extension solo) → see interventions/metformin.md

Combination evidence

Mouse (T3)

Strong et al. 2016, Aging Cell — ITP cohort tested:

• Rapamycin alone (positive)
• Metformin alone (null)
• Rapamycin + metformin (positive, but the combined effect was not meaningfully larger than rapamycin alone)

Interpretation: metformin does not provide additive benefit on top of rapamycin in this cohort. This is informative for the longevity-discourse framing of "stacking" these drugs — the practice is not supported by the ITP data.

Human (T0)

• No formal trial of the rapamycin + metformin combination for aging endpoints.
• Off-label longevity-medicine practice uses both; rationale is largely "rapamycin for the longevity case + metformin for the diabetic / metabolic indication" rather than synergy.
• The MET-PREVENT 2025 finding that metformin blunts exercise adaptations adds another wrinkle: combining rapamycin + metformin in a longevity-curious population that exercises may unintentionally reduce exercise's benefits.

Safety considerations

• Both drugs are well-tolerated in their indicated populations.
• Combined use is not pharmacologically novel — some diabetic patients on metformin who require immunosuppression for transplant or autoimmune disease take both.
• In healthy adults at low doses for longevity: monitoring requirements (lipid, renal, B12, glucose) are non-trivial and adherence costs grow.

Comparison to rapamycin + acarbose

The contrast is informative:

• Rapamycin + acarbose showed clear synergistic benefit in ITP (combined effect larger than either alone)
• Rapamycin + metformin showed effect approximately equal to rapamycin alone

If choosing a "second drug" to add to rapamycin based on ITP evidence, acarbose is the better-supported choice. The popular discourse weighting of metformin > acarbose is inverse to the mouse evidence.

Translation status

For longevity-medicine clinicians:

• Adding metformin to rapamycin is mostly redundant for the longevity case based on ITP data.
• The metformin component may still be appropriate for separate diabetic / metabolic indications.
• The combination is plausibly inferior to rapamycin + acarbose if the goal is longevity benefit.

Calibrated verdict

Probable in mice (driven by rapamycin) / Suggestive in humans. The combination's benefit appears primarily attributable to rapamycin; metformin contributes little additional lifespan effect.

Open questions

• Q: Has a more recent ITP cohort tested this combination, possibly with different doses or initiation timings, that might change the pattern?
• Q: For humans on rapamycin who already have metabolic dysfunction, does metformin's metabolic correction provide indirect longevity-relevant benefit not captured by mouse-aging endpoints?
• Q: In the metformin-blunts-exercise context, does combining rapamycin (which may also blunt some exercise adaptations) compound exercise interference?

Sources

• Strong et al. 2016, Aging Cell — Longer lifespan with rapamycin alone or combined with metformin (ITP)
• See also interventions/rapamycin.md, interventions/metformin.md, and interactions/rapamycin-acarbose.md

Produced under methodology locked 2026-04-24.